JAGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Jaguar Health, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$2.82−0.71 (-20.00%)
Close on Oct 19, 2026
- Market cap
- $2.28M
- P/E (TTM)
- –
- Dividend yield
- –
Jaguar Health, Inc. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Human Health | $27.26M | $28.95M | $11.16M | $11.43M | $11.44M | $11.21M | $11.37M | $10.21M | $9.98M | $9.97M | $9.59M | – | 98.0% | +138.4% |
| Animal Health | $556.00K | $622.00K | $353.00K | $359.00K | $375.00K | $343.00K | $315.00K | $273.00K | $210.00K | $175.00K | $173.00K | – | 2.0% | +48.3% |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License | $19.17M | $19.17M | $172.00K | $172.00K | $172.00K | $172.00K | $129.00K | – | – | – | – | – | 68.9% | +11046.5% |
| Product revenue, net | $8.62M | $10.37M | $11.34M | $11.61M | $11.64M | $11.38M | $11.56M | $10.40M | $10.14M | $10.14M | $9.76M | $10.72M | 31.0% | -25.9% |
| Mytesi | $8.12M | $9.72M | $11.00M | $11.20M | $11.20M | $11.10M | $11.30M | $10.30M | $10.10M | $10.00M | $9.60M | $10.50M | 29.2% | -27.5% |
| Canalevia-CA1 | $342.00K | $402.00K | $148.00K | $155.00K | $172.00K | $138.00K | $160.00K | $154.00K | $129.00K | $142.00K | $130.00K | $115.00K | 1.2% | +98.8% |
| Neonorm | $19.00K | $26.00K | $35.00K | $35.00K | $35.00K | $36.00K | $28.00K | $35.00K | $38.00K | $33.00K | $42.00K | $43.00K | 0.1% | -45.7% |
By region
From the segment and revenue-disaggregation notes of Jaguar Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.